FOR IMMEDIATE RELEASE

May 2, 2014

AnGes MG, Inc.

AnGes Amends Development Strategy of NF-κB Decoy Oligonucleotide for Atopic Dermatitis Treatment Drug

AnGes MG, Inc. (“AnGes”) today announced an amendment to the development strategy of the NF-κB Decoy Oligonucleotide for atopic dermatitis treatment drug under development in partnership with Shionogi & Co., Ltd. (Head Office: Osaka, President and Representative Director, Isao Teshirogi, “Shionogi”).

AnGes and Shionogi have conducted a Phase I Study of the NF-κB Decoy Oligonucleotide external preparation using a transdermal absorption technology by MEDRx (Head Office: Kagawa, President & CEO, Masayoshi Matsumura, “MEDRx”). Upon analysis of the study results, AnGes and Shionogi concluded that development with the current formulation should not be continued, and a new formulation using another transdermal absorption technology for improved skin penetration of the NF-κB Decoy Oligonucleotide should be considered to increase the chances for success of clinical development. AnGes and Shionogi have agreed that further development should be taken under initiative of AnGes, while the partnerships with Shionogi and MEDRx will continue.

NF-κB Decoy Oligonucleotide is a large molecule drug and differs from conventional low molecule drugs. This makes the combination with an effective DDS (Drug Delivery System) to improve skin penetration essential. AnGes will assess other DDSs including another technology also provided by MEDRx and an ointment which has already completed the Phase II study in Japan by AnGes. AnGes will assess applicable DDSs and select the most effective measure to continue development of the NF-κB Decoy Oligonucleotide atopic dermatitis treatment drug.

This event has minimal effect on business performance for the fiscal year 2014, whose forecast will remain unchanged.

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.

AnGesMG, Inc.
Corporate Communications
TEL:+81-3-5730-2641, FAX:+81-3-5730-2635
http://www.anges-mg.com